siRNA tackles cancer: Immune checkpoint inhibitors and siRNA combinations
Molecular Therapy Nucleic Acids · 2025-03 · 36 (1) · 102429
DOI: 10.1016/j.omtn.2024.102429 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Nucleic Acids, 2025-03. Verfasst von Andrew H Coles. Beteiligte Einrichtung: AbbVie Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Since the first approved small interfering RNA (siRNA) drug in 2018, Onpattro for amyloidosis, additional approvals and more indications have followed. Currently, there are numerous liver-targeting siRNA clinical studies, but non-liver indications are also being explored, such as for the CNS. This has been made possible by the efforts of many labs over several years to improve the drug-like properties of siRNAs and delivery to, first, liver and now, extrahepatic tissues.1 One such promising clinical study highlighting the exploration of indications beyond the liver is the phase 1 study being conducted by Comanche Biopharma that utilizes a lipid-conjugated siRNA targeting soluble fms-like tyrosine kinase (sFLT) for preeclampsia.
Autor:innen und Institutionen
- AbbVie Bioresearch Center, 100 Research Drive, Worcester, MA 01605, USA.
Zitieren
APA
Coles, A. H. (2025). siRNA tackles cancer: Immune checkpoint inhibitors and siRNA combinations. Molecular Therapy Nucleic Acids, 36(1), 102429. https://doi.org/10.1016/j.omtn.2024.102429
Vancouver
Coles AH. siRNA tackles cancer: Immune checkpoint inhibitors and siRNA combinations. Molecular Therapy Nucleic Acids. 2025;36(1):102429. doi:10.1016/j.omtn.2024.102429
BibTeX
@article{Coles2025,
author = {Coles, Andrew H},
title = {siRNA tackles cancer: Immune checkpoint inhibitors and siRNA combinations},
journal = {Molecular Therapy Nucleic Acids},
year = {2025},
volume = {36},
number = {1},
pages = {102429},
doi = {10.1016/j.omtn.2024.102429}
}
EUVIMED